Key result
Among 57 patients undergoing colorectal cancer surgery, various VTE prophylaxis regimens resulted in 0 venous thromboembolisms at 30 days, with bleeding in 4 of 18 patients on non-standard regimens.
Why the study?
Venous thromboembolism after colorectal cancer surgery increases morbidity, mortality, recovery time, and costs, prompting an evaluation of discharge prophylaxis prescribing variability and postoperative outcomes.
Do various VTE prophylaxis regimens affect the 30-day incidence of VTE and bleeding in postoperative colorectal cancer patients compared to standard 40 mg enoxaparin daily?
Population
57 patients undergoing surgery for colorectal cancer
Comparison
40 mg enoxaparin daily vs other discharge prophylaxis regimens
Design
Retrospective case series
Follow-up
30-day postoperative period
Authors
Loading...
Small retrospective cohort with zero VTEs should not yet change prophylaxis practice; leaves optimal regimens open for prospective trials.
Observational (n=57)
No
Do various VTE prophylaxis regimens affect the 30-day incidence of VTE and bleeding in postoperative colorectal cancer patients compared to standard 40 mg enoxaparin daily?
Despite variations in VTE prophylaxis regimens for postoperative colorectal cancer patients, VTE rates remained negligible, though bleeding complications occurred in some patients on non-standard regimens.
Perrotti et al. (2020) conducted an observational in colorectal cancer (n=57). Various VTE prophylaxis regimens vs. 40 mg enoxaparin daily was evaluated on 30-day postoperative incidence of venous thromboembolisms and bleeding. Among 57 patients undergoing colorectal cancer surgery, various VTE prophylaxis regimens resulted in 0 venous thromboembolisms at 30 days, with bleeding in 4 of 18 patients on non-standard regimens.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: